论文部分内容阅读
目的探讨血浆中miR-196a、miR-29c与乳腺癌临床病理特征之间的关系,为早期诊断乳腺癌提供新的方法。方法收集31例乳腺癌患者血浆标本及临床病理资料,以20例乳腺正常人血浆标本作为对照,运用RT-PCR方法检测miR-196a、miR-29c在乳腺癌患者和乳腺正常者血浆中的相对表达量,并分析二者与临床病理特征的关系。结果miR-196a、miR-29c在乳腺癌患者血浆中的相对表达量显著高于乳腺正常者(P=0.0019,P<0.0001)。miR-196a的异常表达与肿瘤大小和临床分期相关(P<0.01),与淋巴结转移、雌激素受体、孕激素受体无关(P>0.05)。miR-29c的异常表达与淋巴结转移、临床分期和雌激素受体相关(P<0.01),与肿瘤大小、孕激素受体无关(P>0.05)。结论 miR-196a、miR-29c在乳腺癌患者血浆中显著高表达。血浆中miR-196a、miR-29c的检测有望成为早期诊断乳腺癌的新方法。
Objective To investigate the relationship between the expression of miR-196a and miR-29c in plasma and clinicopathological features of breast cancer, and to provide a new method for the early diagnosis of breast cancer. Methods Plasma samples from 31 patients with breast cancer and clinical pathological data were collected. Twenty normal breast plasma samples were used as controls. The relative plasma levels of miR-196a and miR-29c in breast cancer patients and normal breast tissues were detected by RT-PCR. Expression, and analyze the relationship between the two and clinicopathological features. Results The relative expression of miR-196a and miR-29c in the plasma of patients with breast cancer was significantly higher than that of normal breast (P = 0.0019, P <0.0001). Aberrant expression of miR-196a was correlated with tumor size and clinical stage (P <0.01), but not with lymph node metastasis, estrogen receptor and progesterone receptor (P> 0.05). Aberrant expression of miR-29c correlated with lymph node metastasis, clinical stage and estrogen receptor (P <0.01), but not with tumor size and progesterone receptor (P> 0.05). Conclusion miR-196a and miR-29c are highly expressed in the plasma of breast cancer patients. Detection of plasma miR-196a, miR-29c is expected to be a new method of early diagnosis of breast cancer.